An employee works in a workshop specializing in the production of insulin pens at the plant of U.S. pharmaceutical company Eli Lilly in Fegersheim, eastern France, Oct. 12, 2015.
The Chinese Communist virus (Wuhan pneumonia) pandemic has reduced the risk of hospitalization and death by 87 percent with the company’s combination antibody therapy for COVID-19, a disease caused by the Chinese Communist virus, U.S. drugmaker Eli Lilly said on Wednesday (March 10).
Reuters reported that the company’s claim was based on a study of more than seven hundred and fifty high-risk patients. The second large, post-stage study showed that the combination of bamlanivimab and etesevimab was effective in treating patients with mild to moderate coronavirus (MCT).
In a previous study released in January, the company used higher doses of the drug to reduce the risk of hospitalization by 70 percent.
“We have very few drugs for other diseases that offer this scale of effect.” Daniel Skovronsky, Lilly’s chief scientific officer, said, “I hope these data will continue to drive greater use of antibodies.”
U.S. regulators authorized the combination therapy in February for potentially seriously ill patients aged 12 years and older with CCHV and agreed that month to purchase at least 100,000 doses of the combination therapy drug. European regulators approved its use in March.
Regulators last year authorized bamulanib monotherapy alone for use against the CCHV. Skovronski said the benefit of the combination therapy is to provide greater protection to the recipient from infection with a variant strain of the new coronavirus (CCLV).
The new variant of the CCP virus, initially identified in the United Kingdom, is already present in most U.S. states and is expected to further dominate the U.S. outbreak. According to the study, the variant is not only highly infectious, but also more deadly.
Skovronski said, “We are very confident that this combination will cover all variants in the United States.” Eli Lilly is working on a separate treatment for the new variants first discovered in South Africa and Brazil, which have not yet spread widely in the United States.
Anthony Fauci, the White House’s chief medical adviser, warned Tuesday that the U.S. outbreak is threatening to spike to “a very high level” again.
He also said the U.S. is now assessing the impact of “homegrown” variants, including one believed to have originated in New York. According to the New York Times, the variant, known as B.1.526, is spreading rapidly in New York City. The strain carries a mutation that could weaken the effectiveness of the vaccine.
Currently, two doses of the vaccine from Pfizer and Moderna and one from Johnson & Johnson are being offered to people in the United States.
Skovronsky said Lilly is preparing to produce 1 million doses of the combination therapy drug in the next few months. It is also in active negotiations to offer treatment options to governments around the world.
Recent Comments